MedTrace Logo

Yangxinshi Tablet Intervention for Exercise Capacity in Patients With Chronic Coronary Syndrome

NCT06171061 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 1200

Last updated 2024-04-17

No results posted yet for this study

Summary

This study is a prospective, multicentre, randomized, open-label, blinded-endpoint clinical trial to evaluate the efficacy and safety of Yangxinshi tablets in the treatment of patients with chronic coronary syndrome (CCS).

Conditions

  • Chronic Coronary Syndrome

Interventions

DRUG

Yangxinshi tablet

In addition to basic medication, the experimental group will be given Yangxinshi (three tablets each time, three times a day);The treatment period is 24 weeks.

OTHER

Basic medication

The control group will be given basic medication only. The treatment period is 24 weeks.

Sponsors & Collaborators

  • Shandong First Medical University

    lead OTHER

Principal Investigators

  • Yuan Haitao · Shandong Provincial Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-18
Primary Completion
2025-12-31
Completion
2026-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06171061 on ClinicalTrials.gov